萘莫司他治疗脓毒症的有效性与安全性(EASNMS):多中心随机对照试验研究方案
EASNMS是一项多中心、双盲、随机对照试验,计划纳入778例符合Sepsis 3.0标准的脓毒症患者,按1:1随机接受静脉给予萘莫司他(NM)或葡萄糖,联合标准治疗。主要结局为ICU全因死亡率,次要结局包括SOFA评分改善、JAAM/ISTH评分变化、28天全因死亡率及不良事件发生率。
要点
- 多中心双盲RCT,计划纳入778例Sepsis 3.0脓毒症患者,1:1随机分组。
- 干预为静脉NM或葡萄糖联合标准治疗,主要结局为ICU全因死亡率。
- 次要结局含SOFA改善、JAAM/ISTH评分变化、28天全因死亡率和不良事件。
核心结论
- EASNMS试验旨在评估NM治疗中国不同地区脓毒症患者的有效性与安全性。
- 作者认为NM作为附加治疗选择,可能有望改善脓毒症患者的预后。
研究设计与样本
- 多中心、双盲、随机对照试验,计划招募778例符合Sepsis 3.0标准的受试者。
- 参与者按1:1随机分配接受静脉NM或葡萄糖,联合标准治疗。
- 分配对研究者、参与者和统计师隐藏以保持盲法。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局为ICU全因死亡率。
- 次要结局包括SOFA评分改善、JAAM/ISTH评分变化、28天全因死亡率及不良事件发生率。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is the leading cause of death in critically ill patients, with an in-hospital mortality rate of approximately 25% to 40%. Coagulation activation serves as an initial factor to the progression of sepsis into multiple organ dysfunction syndrome (MODS). Therefore, anticoagulant therapy may be beneficial. Both preclinical experiments and clinical studies have evaluated the protective effect of nafamostat mesilate (NM) in sepsis. However, there is still a lack of randomized controlled trials (RCTs) to further confirm the therapeutic effect and safety of NM in sepsis patients. METHODS: This multicenter, double-blind, RCT was designed to recruit 778 subjects who met Sepsis 3.0 criteria. Participants will be randomly assigned (1:1) to receive either intravenous administration of NM or glucose along with standard treatment. The primary outcome is the all-cause mortality rate in the intensive care unit (ICU), and the secondary outcomes include the improvement in SOFA scores, changes in Japanese Association for Acute Medicine (JAAM)/International Society on Thrombosis and Hemostasis (ISTH) scores, 28-day all-cause mortality rate, and the incidence of adverse events. The allocation will remain concealed from investigators, participants, and statisticians to maintain blinding. DISCUSSION: The EASNMS trial aims to assess the efficacy and safety of NM for treating sepsis across various regions in China. As an additional treatment option, NM may potentially enhance the prognosis of sepsis patients. ETHICS AND DISSEMINATION: Ethical approval has been obtained from all ethics committees of the involved centers. The findings of this study will be shared in peer-reviewed journals and will be presented at conferences. TRIAL REGISTRATION: ClinicalTrials.gov NCT06078839. Registered on September 20, 2023.
引用
- Yang H, Feng J, Ma Y, et al. Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial. Trials. 2025. PMID: 40731293. doi:10.1186/s13063-025-08979-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。